Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: Comparison between iliac crest and lumbar vertebra in ewes

Bone

Volumn 51, Issue 4, 2012, Pages 714-719

  Portero Muzy, N R ^a   Chavassieux, P M ^a   Bouxsein, M L ^b   Gineyts, E ^a   Garnero, P ^a   Chapurlat, R D ^a  

^a UNIVERSITÉ DE LYON   (France)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Ewe; Iliac crest; Teriparatide; Vertebra; Zoledronic acid

Indexed keywords

COLLAGEN; DEOXYPYRIDINOLINE; PARATHYROID HORMONE[1-34]; PENTOSIDINE; PYRIDINOLINE; ZOLEDRONIC ACID;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE BIOPSY; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; ILIAC CREST; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; POROSITY; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN CROSS LINKING; SINGLE DRUG DOSE;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; COLLAGEN; DIPHOSPHONATES; FEMALE; ILIUM; IMIDAZOLES; LUMBAR VERTEBRAE; SHEEP; TERIPARATIDE;

EID: 84865624559     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.07.004     Document Type: Article

References (54)

1. Meunier P., Courpron P. Iliac trabecular bone volume in 236 controls: representativeness of iliac samples. Proceedings of the First Workshop on Bone Morphometry 1973, 100-105.
2. Meunier P., Courpron P., Edouard C., Bernard J., Bringuier J., Vignon G. Physiological senile involution and pathological rarefaction of bone. Quantitative and comparative histological data. Clin Endocrinol Metab 1973, 2:239-256.
3. Podenphant J., Gotfredsen A., Nilas L., Norgaard H., Braendstrup O. Iliac crest biopsy: representativity for the amount of mineralized bone. Bone 1986, 7:427-430.
4. Mosekilde L. Iliac crest trabecular bone volume as predictor for vertebral compressive strength, ash density and trabecular bone volume in normal individuals. Bone 1988, 9:195-199.
5. Amling M., Grote H.J., Posl M., Hahn M., Delling G. Polyostotic heterogeneity of the spine in osteoporosis. Quantitative analysis and three-dimensional morphology. Bone Miner 1994, 27:193-208.
6. Amling M., Herden S., Posl M., Hahn M., Ritzel H., Delling G. Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res 1996, 11:36-45.
7. Recker R.R., Delmas P.D., Halse J., Reid I.R., Boonen S., Garcia-Hernandez P.A., Supronik J., Lewiecki E.M., Ochoa L., Miller P., Hu H., Mesenbrink P., Hartl F., Gasser J., Eriksen E.F. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008, 23:6-16.
8. Hodsman A.B., Kisiel M., Adachi J.D., Fraher L.J., Watson P.H. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 2000, 27:311-318.
9. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., Jasqui S., Donley D.W., Dalsky G.P., Martin J.S., Eriksen E.F. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244-1253.
10. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
11. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443.
12. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
13. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
14. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellstrom D., Pack S., Wenderoth D., Cooper C., Reginster J.Y. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120-126.
15. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., Cannata J., Balogh A., Lemmel E.M., Pors-Nielsen S., Rizzoli R., Genant H.K., Reginster J.Y. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
16. Libouban H., Blouin S., Moreau M.F., Basle M.F., Audran M., Chappard D. Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies. Micron 2008, 39:998-1007.
17. Thomas T., Vico L., Skerry T.M., Caulin F., Lanyon L.E., Alexandre C., Lafage M.H. Architectural modifications and cellular response during disuse-related bone loss in calcaneus of the sheep. J Appl Physiol 1996, 80:198-202.
18. Mitton D., Cendre E., Roux J.P., Arlot M.E., Peix G., Rumelhart C., Babot D., Meunier P.J. Mechanical properties of ewe vertebral cancellous bone compared with histomorphometry and high-resolution computed tomography parameters. Bone 1998, 22:651-658.
19. Chavassieux P., Pastoureau P., Chapuy M.C., Delmas P.D., Meunier P.J. Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int 1993, 3:97-102.
20. Chavassieux P., Pastoureau P., Boivin G., Chapuy M.C., Delmas P.D., Meunier P.J. Dose effects on ewe bone remodeling of short-term sodium fluoride administration-a histomorphometric and biochemical study. Bone 1991, 12:421-427.
21. Chavassieux P., Garnero P., Duboeuf F., Vergnaud P., Brunner-Ferber F., Delmas P.D., Meunier P.J. Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study. J Bone Miner Res 2001, 16:89-96.
22. Chavassieux P., Buffet A., Vergnaud P., Garnero P., Meunier P.J. Short-term effects of corticosteroids on trabecular bone remodeling in old ewes. Bone 1997, 20:451-455.
23. Chavassieux P. Bone effects of fluoride in animal models in vivo. A review and a recent study. J Bone Miner Res 1990, 5(Suppl. 1):S95-S99.
24. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nilssen M.H. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?. Bone 1995, 16:603-610.
25. Garnero P., Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993, 77:1046-1053.
26. Bauer D.C., Garnero P., Hochberg M.C., Santora A., Delmas P., Ewing S.K., Black D.M. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006, 21:292-299.
27. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
28. Chavassieux P.M., Meunier P.J. Clinical use of bone biopsy. Osteoporosis 2001, 501-509. Academic Press, San Diego. 2nd ed. R. Marcus, D. Feldman, J. Kelsey (Eds.).
29. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
30. Parfitt A.M., Mathews C.H., Villanueva A.R., Kleerekoper M., Frame B., Rao D.S. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983, 72:1396-1409.
31. Portero N.R., Arlot M.E., Roux J.P., Duboeuf F., Chavassieux P.M., Meunier P.J. Evaluation and development of automatic two-dimensional measurements of histomorphometric parameters reflecting trabecular bone connectivity: correlations with dual-energy X-ray absorptiometry and quantitative ultrasound in human calcaneum. Calcif Tissue Int 2005, 77:195-204.
32. Viguet-Carrin S., Gineyts E., Bertholon C., Delmas P.D. Simple and sensitive method for quantification of fluorescent enzymatic mature and senescent crosslinks of collagen in bone hydrolysate using single-column high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1-7.
33. Mellish R.W., Ferguson-Pell M.W., Cochran G.V., Lindsay R., Dempster D.W. A new manual method for assessing two-dimensional cancellous bone structure: comparison between iliac crest and lumbar vertebra. J Bone Miner Res 1991, 6:689-696.
34. Davison K.S., Siminoski K., Adachi J.D., Hanley D.A., Goltzman D., Hodsman A.B., Josse R., Kaiser S., Olszynski W.P., Papaioannou A., Ste-Marie L.G., Kendler D.L., Tenenhouse A., Brown J.P. Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum 2006, 36:22-31.
35. Bouxsein M.L., Seeman E. Quantifying the material and structural determinants of bone strength. Best Pract Res Clin Rheumatol 2009, 23:741-753.
36. Wegrzyn J., Roux J.P., Arlot M.E., Boutroy S., Vilayphiou N., Guyen O., Delmas P.D., Chapurlat R., Bouxsein M.L. Role of trabecular microarchitecture and its heterogeneity parameters in the mechanical behavior of ex vivo human L3 vertebrae. J Bone Miner Res 2010, 25:2324-2331.
37. Bouxsein M.L. Determinants of skeletal fragility. Best Pract Res Clin Rheumatol 2005, 19:897-911.
38. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13:97-104.
39. Silva M.J., Gibson L.J. Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone 1997, 21:191-199.
40. Roux J.P., Wegrzyn J., Arlot M.E., Guyen O., Delmas P.D., Chapurlat R., Bouxsein M.L. Contribution of trabecular and cortical components to biomechanical behavior of human vertebrae: an ex vivo study. J Bone Miner Res 2010, 25:356-361.
41. Goulet R.W., Goldstein S.A., Ciarelli M.J., Kuhn J.L., Brown M.B., Feldkamp L.A. The relationship between the structural and orthogonal compressive properties of trabecular bone. J Biomech 1994, 27:375-389.
42. Binkley N., Kimmel D., Bruner J., Haffa A., Davidowitz B., Meng C., Schaffer V., Green J. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998, 13:1775-1782.
43. Allen M.R., Gineyts E., Leeming D.J., Burr D.B., Delmas P.D. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 2008, 19:329-337.
44. Allen M.R., Burr D.B. Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int 2008, 19:95-99.
45. Saito M., Mori S., Mashiba T., Komatsubara S., Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008, 19:1343-1354.
46. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., Shane E., Plavetic K., Muller R., Bilezikian J., Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
47. Dobnig H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., Pavo I., Wang J., Eriksen E.F. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970-3977.
48. Viguet-Carrin S., Follet H., Gineyts E., Roux J.P., Munoz F., Chapurlat R., Delmas P.D., Bouxsein M.L. Association between collagen cross-links and trabecular microarchitecture properties of human vertebral bone. Bone 2010, 46:342-347.
49. Eyre D.R., Dickson I.R., Van Ness K. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem J 1988, 252:495-500.
50. Zioupos P. On microcracks, microcracking, in-vivo, in vitro, in-situ and other issues. J Biomech 1999, 209-211. [213-259].
51. Follet H., Viguet-Carrin S., Burt-Pichat B., Depalle B., Bala Y., Gineyts E., Munoz F., Arlot M., Boivin G., Chapurlat R.D., Delmas P.D., Bouxsein M.L. Effects of preexisting microdamage, collagen cross-links, degree of mineralization, age, and architecture on compressive mechanical properties of elderly human vertebral trabecular bone. J Orthop Res 2011, 29:481-488.
52. Viguet-Carrin S., Roux J.P., Arlot M.E., Merabet Z., Leeming D.J., Byrjalsen I., Delmas P.D., Bouxsein M.L. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 2006, 39:1073-1079.
53. Tang S.Y., Zeenath U., Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007, 40:1144-1151.
54. Vashishth D., Gibson G.J., Khoury J.I., Schaffler M.B., Kimura J., Fyhrie D.P. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001, 28:195-201.